Search Within

Alexander Edward Drilon

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (76)
  2. Meeting Abstract (75)
  3. Research Letter (2)
  4. Book Section (1)
  5. Editorial (1)
  6. Guidelines (1)
Groups
  1. Department of Medicine (156)
  2. GSK Faculty (156)
  3. Human Oncology and Pathogenesis Program (156)
  4. Solid Tumor Oncology Division (156)
  5. Thoracic Oncology (156)
  6. Department of Pathology and Laboratory Medicine (150)

More Groups

People
  1. Marc Ladanyi (121)
  2. Maria Arcila (64)
  3. Mark Kris (54)
  4. Michael Berger (51)
  5. Charles Rudin (45)
  6. Gregory Riely (44)

More People

Years
  1. 2025 (2)
  2. 2024 (12)
  3. 2023 (9)
  4. 2022 (17)
  5. 2021 (14)
  6. 2020 (13)

More Years

Publications
  1. Journal of Clinical Oncology (33)
  2. Journal of Thoracic Oncology (19)
  3. Clinical Cancer Research (17)
  4. Cancer Research (9)
  5. JCO Precision Oncology (9)
  6. Cancer Discovery (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (43)
  2. American Association for Cancer Research (36)
  3. Elsevier Inc. (22)
  4. Nature Publishing Group (14)
  5. Oxford University Press (9)
  6. Elsevier Science, Inc. (8)

More Publishers

Results (156)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pan-TRK IHC is an efficient and reliable screening assay for targetable NTRK fusions
    Meeting Abstract

    Hechtman, J. F.; Drilon, A.; Hyman, D. M.; Zehir, A.; Dogan, S.; Arcila, M. E.; Ladanyi, M.; Benayed, R.; Jungbluth, A.
    Laboratory Investigation (2017)

    Fulltext@MSK | Save
  • MDM2 amplification (Amp) to mediate cabozantinib resistance in patients (Pts) with advanced RET-rearranged lung cancers
    Meeting Abstract

    Somwar, R.; Smith, R.; Hayashi, T.; Ishizawa, K.; Charen, A. S.; Khodos, I.; Mattar, M.; He, J.; Balasubramanian, S.; Stephens, P.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Next generation sequencing (NGS) in lung adenocarcinoma (LA) as a guide to treatment selection
    Meeting Abstract

    Jordan, E.; Barron, D.; Schultz, N.; Chakravarty, D.; Kris, M. G.; Rudin, C. M.; Li, B. T.; Yu, H. A.; Drilon, A. E.; Rusch, V. W.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Overcoming drug resistance to Trk inhibition by rational combination of entrectinib and trametinib: From bench to bedside
    Meeting Abstract

    Ho, A.; Wei, G.; Maneval, E. C.; Esquibel, V.; Berger, M. F.; Haque, S.; Patel, R.; Walsh, C.; Hornby, Z.; Multani, P.; more...
    European Journal of Cancer (2016)

    Fulltext@MSK | Save
  • Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
    Journal Article

    Drilon, A.; Rekhtman, N.; Arcila, M.; Wang, L.; Ni, A.; Albano, M.; Van Voorthuysen, M.; Somwar, R.; Smith, R. S.; Montecalvo, J.; more...
    Lancet Oncology (2016)

    Fulltext@MSK | Save
  • Detection of ALK alternative transcription initiation and MET exon 14 skipping using nanoString digital nCounter technology in a clinical setting
    Meeting Abstract

    Borsu, L.; Mullaney, K.; Benayed, R.; Chi, P.; Busam, K.; Paik, P.; Drilon, A.; Ladanyi, M.
    Journal of Molecular Diagnostics (2016)

    Fulltext@MSK | Save
  • Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets
    Journal Article

    Rekhtman, N.; Pietanza, M. C.; Hellmann, M. D.; Naidoo, J.; Arora, A.; Won, H.; Halpenny, D. F.; Wang, H.; Tian, S. K.; Litvak, A. M.; more...
    Clinical Cancer Research (2016)

    Fulltext@MSK | Save
  • Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers
    Journal Article

    Drilon, A.; Bergagnini, I.; Delasos, L.; Sabari, J.; Woo, K. M.; Plodkowski, A.; Wang, L.; Hellmann, M. D.; Joubert, P.; Sima, C. S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer
    Journal Article

    Drilon, A.; Somwar, R.; Wagner, J. P.; Vellore, N. A.; Eide, C. A.; Zabriskie, M. S.; Arcila, M. E.; Hechtman, J. F.; Wang, L.; Smith, R. S.; more...
    Clinical Cancer Research (2016)

    Fulltext@MSK | Save
  • What hides behind the MASC: Clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
    Journal Article

    Drilon, A.; Li, G.; Dogan, S.; Gounder, M.; Shen, R.; Arcila, M.; Wang, L.; Hyman, D. M.; Hechtman, J.; Wei, G.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save